Last reviewed · How we verify

Tri-luma

Hexsel Dermatology Clinic · FDA-approved active Small molecule

Tri-Luma is a topical combination that inhibits melanin production and reduces hyperpigmentation through multiple mechanisms including tyrosinase inhibition and corticosteroid activity.

Tri-Luma is a topical combination that inhibits melanin production and reduces hyperpigmentation through multiple mechanisms including tyrosinase inhibition and corticosteroid activity. Used for Melasma (chloasma).

At a glance

Generic nameTri-luma
SponsorHexsel Dermatology Clinic
Drug classTopical depigmenting agent combination
TargetTyrosinase; retinoic acid receptor; glucocorticoid receptor
ModalitySmall molecule
Therapeutic areaDermatology
PhaseFDA-approved

Mechanism of action

Tri-Luma contains hydroquinone (a tyrosinase inhibitor that blocks melanin synthesis), tretinoin (a retinoid that increases cell turnover and reduces pigment deposition), and fluocinolone acetonide (a corticosteroid that reduces inflammation and melanin production). Together, these three agents work synergistically to lighten hyperpigmented areas of skin.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: